The ABCA13 Knockout MGC-803 Cell Line is a CRISPR/Cas9-edited knockout cell line engineered to disrupt the ABCA13 gene in the human MGC-803 gastric adenocarcinoma background. This targeted gene disruption provides a stable loss-of-function model that enables detailed functional dissection of ABCA13 in a cancer-relevant cellular context. The cell line is supplied as a ready-to-use adherent culture suitable for a wide range of in vitro applications without requiring additional genetic manipulation.
MGC-803 is a human gastric adenocarcinoma cell line established from metastatic ascites, widely used as a gastric cancer model. It recapitulates aggressive cancer features including rapid proliferation, chromosomal instability, and intrinsic chemoresistance. This background is suited for studying gastric tumorigenesis, metastasis, and drug resistance, making it an ideal host for investigating genes involved in lipid-mediated signaling and drug response.
ABCA13 encodes a poorly characterized ATP-binding cassette transporter putatively mediating intracellular lipid transport and membrane trafficking. It is thought to function in vesicle-mediated lipid movement, influencing ceramide metabolism, membrane lipid composition, and apoptotic signaling. Upstream regulation may involve the tumor suppressor p53 and cellular stress pathways, while interactions with other ABC transporters and membrane scaffold proteins help orchestrate lipid homeostasis. Disruption of ABCA13 likely disturbs lipid raft organization, ceramide distribution, and apoptotic factor activity, thereby impacting cell survival and drug response.
In MGC-803 cells, ABCA13 disruption offers a platform to explore contributions of lipid transporter dysfunction to gastric cancer progression and multidrug resistance. Gastric tumors often display dysregulated lipid metabolism and chemoresistance; this knockout model permits investigation of links between ABCA13-dependent lipid handling, p53 status, and apoptotic threshold. Thus, it is a valuable tool for dissecting molecular mechanisms of gastric cancer adaptation and therapy failure.
The ABCA13 Knockout MGC-803 Cell Line supports a diverse array of experimental approaches, including cell proliferation assays to measure growth kinetics, Annexin V apoptosis assays to quantify programmed cell death, and MTT-based drug sensitivity assays to evaluate chemotherapeutic response. Lipidomic profiling can be employed to map changes in lipid species distribution, while migration assays assess metastatic potential. Gene expression analysis by RT-qPCR and protein-level validation via Western blotting enable downstream target verification. For further technical information or experimental support, contact Ascent Research.
